Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Novo Nordisk A/S (NYSE: NVO ) stock is trading lower on Tuesday despite the company raising its fiscal 2026 guidance. The weight loss drug maker reported second quarter sales of 78.488 billion Danish kroner, up 2% year over year (+3% at constant currency). However, the sales were down 19% from the first quarter sales of 96.823 billion Danish kroner. Novo Nordisk said the growth was negatively impacted by a DKK 2.6 billion rebate provision reversal related to the 340B Drug Pricing Program in the second quarter of 2025, creating a tough comparison for the second quarter of 2026. The company reported adjusted earnings of 6.18 Danish kroner, up 5%. Read Also: Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients Second quarter operating profit decreased by 16% at CER to 27.061 billion, or 19% overall, with growth negatively impacted by the U...